2005 NNFF Consortium for NF1, NF2 and Schwannomatosis

描述(由申请者提供)：申请资助将于2005年6月5日至8日在科罗拉多州阿斯彭的杰罗姆酒店举行的NF1、NF2和神经鞘瘤病的分子和细胞生物学国家神经纤维瘤基金会国际联合会2005年会议。从1985年的第一次会议开始，这些会议提供了一个定期论坛，将科学家和临床医生聚集在一起，分享他们最新的研究成果和经验，并建立新的合作项目。NNFF联盟在许多关键研究成果中发挥了重要作用，包括克隆基因、探索蛋白质功能、开发动物模型以及创建患者和临床医生网络以促进临床试验。快速的科学进步和随后的临床实践使年度会议既具有科学生产力，又具有必要性。2005年联合会会议将是向一般科学界宣传的一次公开会议。五次平台会议中的每一次都将包括实地专家，他们将指导受邀发言者提出的工作的讨论和选定的提交摘要。将鼓励初级调查人员参加，组织者预计，在以往联合会会议的基础上，发言者中将有相当大比例是年轻调查人员。此外，在科学会议中，还将包括来自非国家核力量社区的主旨演讲者所作的更长时间的演讲。还将举行两次海报会议，允许调查人员介绍其中一次口头会议没有选择的摘要。除了向研究NF1、NF2和神经鞘瘤病的研究人员通报最新研究进展外，这次会议还将有助于确定我们知识中的关键差距以及解决这些差距的战略和合作，并将在开发这些疾病并发症的改进疗法方面发挥重要作用，对发育神经生物学和癌症研究领域具有广泛影响。

DESCRIPTION (provided by applicant): Funding is requested to support the 2005 meeting of the National Neurofibromatosis Foundation International Consortium for the Molecular and Cell Biology of NF1, NF2 and Schwannomatosis, to be held June 5-8, 2005, at the Hotel Jerome in Aspen, Colorado. Beginning with the first meeting in 1985, these conferences have provided a regular forum to bring together scientists and clinicians to share their latest research findings and experiences and to form new collaborative ventures. NNFF Consortia have been instrumental in a number of key research accomplishments, including the cloning of the genes, exploration of protein functions, development of animal models/and creation of a network of patients and clinicians to facilitate clinical trials. The rapid scientific progress and subsequent translation to clinical practice has made annual meetings both scientifically productive and necessary. The 2005 Consortium meeting will be an open meeting advertised to the general scientific community. Each of five platform sessions will include experts in the field who will guide discussion of the presented work from invited speakers and selected submitted abstracts. Participation by junior investigators will be encouraged and the organizers anticipate, on the basis of previous Consortium meetings, that a substantial percentage of the speakers will be young investigators. In addition, longer talks by keynote speakers from outside the NF community will be incorporated into the scientific sessions. Two poster sessions will also be held which will allow investigators to present abstracts not selected for one of the oral sessions. In addition to updating investigators working on NF1, NF2, and schwannomatosis on the latest research developments, this meeting will help to identity critical gaps in our knowledge as well as strategies and collaborations to address them and will play an essential role in developing improved therapies for the complications of these disorders with broad implications to the fields of developmental neurobiology and cancer research.